Open AccessPredictive value of excision repair cross-complementation group 1 protein in locoregionally advanced nasopharyngeal carcinomas receiving cisplatin-based concurrent chemoradiotherapy
Author(s) -
Juan Zhou,
Dong Wang,
Jihua Zheng,
Zhu Wang,
Bo Xie,
Weimin Zhang
Publication year - 2018
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.165866
Subject(s) - ercc1 , oncology , nasopharyngeal carcinoma , medicine , chemoradiotherapy , univariate analysis , cisplatin , proportional hazards model , predictive marker , survival analysis , radiation therapy , multivariate analysis , chemotherapy , cancer , biology , nucleotide excision repair , dna repair , gene , biochemistry
To investigate the ability of excision repair cross-complementation group 1 (ERCC1) protein to predict cisplatin-based concurrent chemoradiotherapy (CCRT) response in locoregionally advanced nasopharyngeal carcinoma (NPC).